![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
I Aramori, H Nirei, M Shoubo, K Sogabe, K Nakamura, H Kojo, Y Notsu, T Ono and S Nakanishi
Exploratory Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Tsukuba, Japan.
We investigated the receptor-binding properties and the antagonist activities of FR139317, a novel endothelin (ET) antagonist, in transfected Chinese hamster ovary cells permanently expressing the two ET receptor subtypes (ETA and ETB). In displacement analysis using membrane preparations derived from the receptor-expressing cells, FR139317 showed a high affinity for ETA (Ki = 1 nM) and a lower affinity for ETB (Ki = 7.3 microM). FR139317 inhibited ETA-mediated phosphatidylinositol hydrolysis and arachidonic acid release and produced a parallel shift in the dose-response curve for ET-1, with respective pA2 values of 8.2 and 7.7. In contrast, FR139317 had no inhibitory effects on these ET-1-induced responses in ETB-expressing cells. FR139317 itself showed no stimulatory effects on phosphatidylinositol hydrolysis and arachidonic acid release in ETA- and ETB-expressing cells. Thus, FR139317 is a potent, competitive, and highly selective antagonist for ETA. This compound should be a powerful tool for investigation of the physiological properties of ETA and exploration of its role in diseases.
This article has been cited by other articles:
|
|
 |
|
  A. Wackenfors, R. Ingemansson, and M. Malmsjo Endothelin receptors in endothelium-denuded human coronary artery bypass grafts and coronary arteries Ann. Thorac. Surg., March 1, 2003; 75(3): 874 - 881. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Davenport International Union of Pharmacology. XXIX. Update on Endothelin Receptor Nomenclature Pharmacol. Rev., June 1, 2002; 54(2): 219 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. FERNANDEZ-PATRON, C. ZOUKI, R. WHITTAL, J. S. D. CHAN, S. T. DAVIDGE, and J. G. FILEP Matrix metalloproteinases regulate neutrophil-endothelial cell adhesion through generation of endothelin-1[1-32] FASEB J, October 1, 2001; 15(12): 2230 - 2240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Araki, K. Hasegawa, E. Iwai-Kanai, M. Fujita, T. Sawamura, T. Kakita, H. Wada, T. Morimoto, and S. Sasayama Endothelin-1 as a protective factor against beta-adrenergic agonist-induced apoptosis in cardiac myocytes J. Am. Coll. Cardiol., October 1, 2000; 36(4): 1411 - 1418. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Salter and R. Z. Kozlowski Differential Electrophysiological Actions of Endothelin-1 on Cl- and K+ Currents in Myocytes Isolated from Aorta, Basilar and Pulmonary Artery J. Pharmacol. Exp. Ther., March 1, 1998; 284(3): 1122 - 1131. [Abstract] [Full Text]
|
|
|
|
 |
|
 I. Aramori, J. Zenkoh, N. Morikawa, N. O'Donnell, M. Asano, K. Nakamura, M. Iwami, H. Kojo, and Y. Notsu Novel Subtype-Selective Nonpeptide Bradykinin Receptor Antagonists FR167344 and FR173657 Mol. Pharmacol., February 1, 1997; 51(2): 171 - 176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Wenzel, N. Duthiers, G. Noll, J. Bucher, U. Kaufmann, and T. F. Luscher Endothelin and Calcium Antagonists in the Skin Microcirculation of Patients With Coronary Artery Disease Circulation, August 1, 1996; 94(3): 316 - 322. [Abstract] [Full Text]
|
|
|
|
|
|
C. R. Cannan, J. C. Burnett Jr, R. R. Brandt, and A. Lerman Endothelin at Pathophysiological Concentrations Mediates Coronary Vasoconstriction via the Endothelin-A Receptor Circulation, December 1, 1995; 92(11): 3312 - 3317. [Abstract] [Full Text]
|
|
|
|
|
|
M. Okada, C. Yamashita, M. Okada, and K. Okada Role of Endothelin-1 in Beagles With Dehydromonocrotaline-Induced Pulmonary Hypertension Circulation, July 1, 1995; 92(1): 114 - 119. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
